Caribou Biosciences Reports Third Quarter 2026 Financial Results
Caribou Biosciences reported its financial results for the third quarter of 2026, highlighting a net loss of $26.6 million and ongoing strategic restructuring efforts.
Stocks · News reference
HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral
HC Wainwright & Co. analyst Robert Burns downgrades Caribou Biosciences (NASDAQ:CRBU) from Buy to Neutral.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Caribou Biosciences Announces Acceptance of Clinical Abstracts for 2026 ASH Annual Meeting
Caribou Biosciences announced that clinical abstracts for its vispa-cel and CB-011 programs have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting.
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.
This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.
This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Analysts downgraded STZ, TYL, DK, CRBU and PSX; price targets changed for STZ, TYL, DK and PSX.
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.